ABSTRACT

The Non-alcoholic liver fatty disease (NAFLD) impacts many developed countries on up to one-third of the population, and it is a growing outbreak. Non-alcoholic steatohepatitis (NASH) can further results in cirrhosis, between 10% to 30% of NAFLD patients. Many risk factors in NAFLD development were supported because most NAFLD's pathophysiology has some kind of metabolic disarrangement and it can be resistant to insulin. Patients with NAFLD are more likely to experience both hepatic and cardiovascular mortality. The standard for definite diagnosis is Liver Biopsy; however, the development of advanced, noninvasive imagery, biochemical and genetic tests will certainly offer future clinicians much information and opportunities for enhanced intelligence and targeted treatment on pathogenesis. Their management largely depends on the disease stage and emphasizes that careful stratification of the risk is essential. In this review, we described the functions of NAFLD and the receptors involved in the differential diagnosis, which helps to understand this disease and manage NAFLD patients more effectively. Keywords: Liver biopsy, NASH, PPAR- ?,PPAR- ? / ?. PPAR- ?
Publication date: 01/11/2022

https://ijbpas.com/pdf/2022/November/MS_IJBPAS_2022_6550.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.11.6550